CA2422303A1 - Breast cancer prognostic portfolio - Google Patents
Breast cancer prognostic portfolio Download PDFInfo
- Publication number
- CA2422303A1 CA2422303A1 CA002422303A CA2422303A CA2422303A1 CA 2422303 A1 CA2422303 A1 CA 2422303A1 CA 002422303 A CA002422303 A CA 002422303A CA 2422303 A CA2422303 A CA 2422303A CA 2422303 A1 CA2422303 A1 CA 2422303A1
- Authority
- CA
- Canada
- Prior art keywords
- genes
- txt
- portfolio
- seq
- cds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 17
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 112
- 230000014509 gene expression Effects 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 51
- 206010027476 Metastases Diseases 0.000 claims abstract description 10
- 230000009401 metastasis Effects 0.000 claims abstract description 8
- 238000002493 microarray Methods 0.000 claims description 22
- 238000004393 prognosis Methods 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 96
- 239000000523 sample Substances 0.000 description 24
- 238000005259 measurement Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101150106899 28 gene Proteins 0.000 description 2
- 101150094765 70 gene Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108700005087 Homeobox Genes Proteins 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 108700005376 Cartilage Oligomeric Matrix Proteins 0.000 description 1
- 102000004201 Ceramidases Human genes 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 description 1
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101000690769 Mus musculus All-trans-retinol dehydrogenase [NAD(+)] ADH7 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- 102100036428 Spondin-1 Human genes 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- 101710140697 Tumor protein 63 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011550 data transformation method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010069264 keratinocyte CD44 Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 102000027424 natriuretic peptide receptors Human genes 0.000 description 1
- 108091008599 natriuretic peptide receptors Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 208000005631 pseudoachondroplasia Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36878902P | 2002-03-29 | 2002-03-29 | |
| US60/368,789 | 2002-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2422303A1 true CA2422303A1 (en) | 2003-09-29 |
Family
ID=29215884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002422303A Abandoned CA2422303A1 (en) | 2002-03-29 | 2003-03-28 | Breast cancer prognostic portfolio |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7473526B2 (https=) |
| EP (1) | EP1367138B1 (https=) |
| JP (1) | JP2003325192A (https=) |
| KR (1) | KR20030078805A (https=) |
| CN (1) | CN1495274A (https=) |
| AR (1) | AR039213A1 (https=) |
| AU (1) | AU2003203557B2 (https=) |
| BR (1) | BR0303092A (https=) |
| CA (1) | CA2422303A1 (https=) |
| DE (1) | DE60317606T2 (https=) |
| MX (1) | MXPA03002864A (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| US20050003422A1 (en) * | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| ES2504242T3 (es) * | 2004-02-20 | 2014-10-08 | Janssen Diagnostics, Llc | Pronóstico de cáncer de mama |
| WO2005106043A2 (en) * | 2004-04-23 | 2005-11-10 | Exagen Diagnostics, Inc. | Breast cancer gene expression biomarkers |
| US20070130694A1 (en) * | 2005-12-12 | 2007-06-14 | Michaels Emily W | Textile surface modification composition |
| EP2295561A3 (en) * | 2006-02-03 | 2011-06-29 | Oriental Yeast Co., Ltd. | Gene group applicable to cancer prognostication |
| WO2008073578A2 (en) | 2006-12-08 | 2008-06-19 | Iowa State University Research Foundation, Inc. | Plant genes involved in nitrate uptake and metabolism |
| US9458495B2 (en) * | 2008-07-01 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and systems for assessment of clinical infertility |
| ES2338843B1 (es) * | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| GB0821787D0 (en) * | 2008-12-01 | 2009-01-07 | Univ Ulster | A genomic-based method of stratifying breast cancer patients |
| US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
| CA2818890C (en) | 2010-11-23 | 2022-07-12 | Krisani Biosciences (P) Ltd | Method and system for prognosis and treatment of diseases using portfolio of genes |
| KR101287600B1 (ko) * | 2011-01-04 | 2013-07-18 | 주식회사 젠큐릭스 | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US635152A (en) * | 1899-06-05 | 1899-10-17 | Melancthon S Shotwell | Car-body bolster. |
| US6350576B1 (en) | 1994-12-20 | 2002-02-26 | Cold Spring Harbor Laboratory | Cancer detection probes |
| EP0871768B1 (en) | 1995-03-17 | 2004-07-07 | John Wayne Cancer Institute | Detection of melanoma metastases with a multiple marker assay |
| US6275814B1 (en) | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| US6037129A (en) | 1998-05-28 | 2000-03-14 | Medical University Of South Carolina | Multi-marker RT-PCR panel for detecting metastatic breast cancer |
| US6175624B1 (en) * | 1999-03-05 | 2001-01-16 | Centurion International, Inc. | Method for connecting a battery circuit in a cellular telephone |
| AU3755300A (en) | 1999-03-15 | 2000-10-04 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| WO2000058473A2 (en) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| US6175824B1 (en) | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
| IL147657A0 (en) | 1999-07-15 | 2002-08-14 | Res Dev Foundation | Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| AU2003217421A1 (en) * | 2002-02-19 | 2003-09-09 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
| US20050054826A1 (en) * | 2003-05-19 | 2005-03-10 | Rosetta Inpharmatics Llc | Human diaphanous-3 gene and methods of use therefor |
-
2003
- 2003-03-21 US US10/393,590 patent/US7473526B2/en not_active Expired - Fee Related
- 2003-03-28 BR BR0303092-0A patent/BR0303092A/pt not_active IP Right Cessation
- 2003-03-28 CA CA002422303A patent/CA2422303A1/en not_active Abandoned
- 2003-03-28 AU AU2003203557A patent/AU2003203557B2/en not_active Expired - Fee Related
- 2003-03-29 CN CNA031312063A patent/CN1495274A/zh active Pending
- 2003-03-29 KR KR10-2003-0019842A patent/KR20030078805A/ko not_active Withdrawn
- 2003-03-31 MX MXPA03002864A patent/MXPA03002864A/es not_active Application Discontinuation
- 2003-03-31 EP EP03252026A patent/EP1367138B1/en not_active Revoked
- 2003-03-31 DE DE60317606T patent/DE60317606T2/de not_active Expired - Fee Related
- 2003-03-31 JP JP2003097226A patent/JP2003325192A/ja active Pending
- 2003-04-01 AR ARP030101134A patent/AR039213A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003203557A1 (en) | 2003-10-23 |
| AU2003203557B2 (en) | 2007-05-24 |
| EP1367138A2 (en) | 2003-12-03 |
| KR20030078805A (ko) | 2003-10-08 |
| DE60317606D1 (de) | 2008-01-03 |
| EP1367138A3 (en) | 2004-03-10 |
| AR039213A1 (es) | 2005-02-09 |
| DE60317606T2 (de) | 2008-10-23 |
| JP2003325192A (ja) | 2003-11-18 |
| MXPA03002864A (es) | 2004-08-11 |
| US7473526B2 (en) | 2009-01-06 |
| CN1495274A (zh) | 2004-05-12 |
| BR0303092A (pt) | 2004-09-08 |
| US20030190656A1 (en) | 2003-10-09 |
| EP1367138B1 (en) | 2007-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7348142B2 (en) | Cancer diagnostic panel | |
| US20100009371A1 (en) | Selection of markers | |
| US12492432B2 (en) | Tumor grading and cancer prognosis | |
| JP5295761B2 (ja) | 甲状腺穿刺吸引分子分析 | |
| US20050239079A1 (en) | Predicting outcome with tamoxifen in breast cancer | |
| BRPI0708534A2 (pt) | ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b | |
| EP1754795A1 (en) | Predicting bone relapse of breast cancer | |
| KR20100120657A (ko) | Ⅱ기 및 ⅲ기 결장암의 분자적 병기 및 예후 | |
| BRPI0616090A2 (pt) | métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida | |
| WO2005054508A2 (en) | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters | |
| EP1526186A2 (en) | Colorectal cancer prognostics | |
| CA2422303A1 (en) | Breast cancer prognostic portfolio | |
| CA2556890A1 (en) | Breast cancer prognostics | |
| US20050186577A1 (en) | Breast cancer prognostics | |
| CA2504403A1 (en) | Prognostic for hematological malignancy | |
| CA2422298C (en) | Colorectal cancer diagnostics | |
| EP1355151A2 (en) | Assessing colorectal cancer | |
| KR20070090110A (ko) | 위 암종으로부터의 림프절 전이의 검출법 | |
| CA2475769A1 (en) | Colorectal cancer prognostics | |
| US20100047787A1 (en) | Prostate cancer survival and recurrence | |
| EP1679382A2 (en) | Panel of nucleic acid sequences for cancer diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |